SHS Gesellschaft fuer Beteiligungsmanagement, MBG Baden-Württemberg and VC Fonds BW announced that SHS has sold its shareholding in Emerging Implant Technologies (EIT), a manufacturer of 3D-printed titanium interbody implants for spinal fusion surgery, to Johnson & Johnson Medical.
SHS became EIT’s lead investor in September 2016 and has supported the company’s growth strategy ever since. Financial terms of the deal have not been disclosed.
“SHS’s objective was to support EIT on their path to increased growth. This includes the development of the company’s innovative product portfolio as well as entering new countries. We’re delighted to have had such a successful partnership with EIT and its employees. We look forward to see EIT´s unique products and Cellular Titanium technology benefit from DePuy Synthes global commercial infrastructure and products. We wish EIT all the best in their future development and trust that the company is in good hands with its new owners,” says Dr Bernhard Schirmers, Managing Partner of SHS, lead investor with EIT.
Guntmar Eisen, Founder and Chief Executive Officer of EIT, says: “The EIT team is passionate about the work we do every day to develop 3D-printed titanium spinal implants. We are proud of what we have achieved with the EIT cellular titanium cages and we are excited to bring this innovative technology to DePuy Synthes, and to customers around the world.”
